Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Coherus Bio (NQ: CHRS )

10.80 -0.61 (-5.35%)
Streaming Delayed Price Updated: 12:18 PM EDT, Aug 9, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 283,505
Open 11.21
Bid (Size) 10.80 (5)
Ask (Size) 10.83 (3)
Prev. Close 11.41
Today's Range 10.80 - 11.39
52wk Range 5.600 - 19.32
Shares Outstanding 77,724,589
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
This Healthcare Stock Is Trading Higher By 148%: Here Are 40 Stocks Moving Premarket
Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares rose 159.3% to $1.67 in pre-market trading after dropping 13% on Tuesday. 
Via Benzinga

Performance

YTD
-34.19%
-34.19%
1 Month
+31.39%
+31.39%
3 Month
+34.50%
+34.50%
6 Month
-8.32%
-8.32%
1 Year
-18.00%
-18.00%

More News

Read More
Recap: Coherus BioSciences Q1 Earnings
Via Benzinga
FDA Rejects Junshi - Coherus' Toripalimab For Rare Head & Neck Cancer
Via Benzinga
Junshi Biosciences - Coherus Toripalimab Chemo Combo Met Survival Endpoints In Lung Cancer Setting
Via Benzinga
Coherus's Refiling For Head and Neck Cancer Candidate Accepted By FDA For Review
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022
Via Benzinga
Week In Review: Zhaoke Signs $130 Million Deal For Vision-Improving Eyedrops
Via Talk Markets
Recap: Coherus BioSciences Q4 Earnings
Via Benzinga
Earnings Scheduled For February 17, 2022
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Week In Review: OrbiMed Plans To Raise $1.1 Billion For Fifth Asia Fund
Via Talk Markets
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Via Benzinga
Earnings Outlook For Coherus BioSciences
Via Benzinga
Coherus and Junshi Biosciences Receive CRL from FDA for Toripalimab in combination with Gemcitabine and Cisplatin In metastatic nasopharyngeal carcinoma (NPC)
Via Benzinga
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
Via Benzinga
AbbVie, Alvotech Resolve US Patent Dispute Related To Humira Biosimilar
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2022
Via Benzinga
Coherus BioSciences' Q4 Sales Fall 34% On Lower Udenyca Volume, Prices
Via Benzinga
The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios
Via Benzinga
A Preview Of Coherus BioSciences's Earnings
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.